NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Abstract Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and the neutrophil-to-lymphocyte ratio (NLR) are routinely measured; lower ALT and higher NLR have been reported in Parkinson's disease (PD), but longitudinal evidence remains limited. In this prospective cohort study, we analyzed longitudinal data from the BEAT-PD cohort, comparing 175 individuals with PD (63 idiopathic, 51 LRRK2 -PD, 61 GBA1 -PD) to 345 non-manifesting individuals (74 LRRK2 , 94 GBA1 , 177 healthy controls). ALT was consistently lower in PD and declined longitudinally, while increasing slightly in controls over a median 4-year follow-up. Lower ALT was associated with longer disease duration independent of dopaminergic medication dosage, suggesting the decline may reflect disease biology rather than a pharmacological effect. AST and NLR differences were less consistent. Analyte levels did not differ significantly across genetic PD subgroups. These findings support ALT as a candidate biomarker of PD risk and progression, though effect sizes were small and not currently clinically actionable.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.